Physician profile
Kelsey U Ryan
NPI 1891138343
$2,306.35
in general payments reported to CMS, 2019-2025
33 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.42 · 2020: $13.91 · 2021: $52.19 · 2023: $838 · 2024: $658 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,208.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.77 | 2023-2025 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $256.19 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $157.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $151.57 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $146.73 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Kowa Pharmaceuticals America, INC. | $109.47 | 2024-2025 | Zoryve |
| Roche Diagnostics Corporation | $70.79 | 2019-2021 | |
| Pfizer INC. | $62.12 | 2023-2025 | |
| Biogen, INC. | $52.85 | 2025 | Zurzuvae |
| Seqirus USA INC | $46.78 | 2024-2025 | Fluad, Flucelvax |
| Takeda Pharmaceuticals U.S.A., INC. | $44.00 | 2023 | Trintellix |
| Ardelyx, INC. | $36.23 | 2024-2025 | Ibsrela |
| Abbott Laboratories | $35.75 | 2023 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $34.82 | 2023 | Ingrezza |
| Mylan Specialty L.P. | $33.78 | 2023-2024 | Yupelri |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $33.26 | 2023-2024 | Adzenys Xr-Odt |
| Glaxosmithkline, LLC. | $31.17 | 2023 | Shingrix, Arexvy |
| Sumitomo Pharma America, INC. | $30.93 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.51 | 2023-2024 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.30 | 2024 | Xifaxan |
| Paratek Pharmaceuticals, INC. | $29.04 | 2023-2024 | Nuzyra |
| Astellas Pharma US INC | $28.04 | 2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $24.53 | 2023 | |
| Vanda Pharmaceuticals INC. | $23.04 | 2024 | Fanapt, Hetlioz |
| Hologic Sales and Service, LLC | $20.24 | 2023 | Aptima, Thinprep 2000 Processor |
| Lundbeck LLC | $18.81 | 2023 | Vyepti |
| Dexcom, INC. | $17.34 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.14 | 2023 | Nuedexta |
| Boston Scientific Corporation | $15.35 | 2024 | |
| Shield Therapeutics INC | $14.50 | 2025 | |
| Merck Sharp & Dohme LLC | $13.91 | 2020 | |
| Coopersurgical, INC. | $12.82 | 2019 | |
| Organon LLC | $7.67 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.